Market Place
Sourcing Support
Resolutions at BioInvent`s Annual General Meeting 2024
03 May 2024 //
PHARMIWEB
Transgene & BioInvent - First Patient Treated in Phase I Trial Assessing BT-001
10 Oct 2023 //
BUSINESSWIRE
Transgene and BioInvent report positive data for oncolytic virus
25 May 2023 //
CLINICAL TRIALS ARENA
Transgene and BioInvent Joint Paper on BT-001 Wins JITC Award
14 Nov 2022 //
BUSINESSWIRE
CASI & Bioinvent Announce Dosing of First Patient In Bi-1206 Phase 1 Trial
07 Sep 2022 //
PRNEWSWIRE
BioInvent Enrolls First Patient in PI/IIa Trial of BI-1607
01 Aug 2022 //
ACCESSWIRE
Transgene, BioInvent Announce Trial Collaboration and Supply Agreement with MSD
27 Jun 2022 //
BUSINESSWIRE
Transgene and BioInvent Announce Positive Progress for BT-001
27 Jun 2022 //
BUSINESSWIRE
Exelixis taps into cancer antibody discoverer out of Sweden
17 Jun 2022 //
ENDPTS
Exelixis and BioInvent Establish Exclusive Option and License Agreement
16 Jun 2022 //
BIOSPACE
FDA Grants ODD to BioInvent`s BI-1206 for follicular lymphoma.
20 Jan 2022 //
PRNEWSWIRE
BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus
09 Nov 2021 //
BIOINVENT
Transgene, BioInvent Present Preclinical Data of BT-001 at SITC 2021
09 Nov 2021 //
BUSINESSWIRE
BioInvent to show further positive BI-1206 clinical data in December at ASH 2021
04 Nov 2021 //
PRESS RELEASE
Transgene and BioInvent to present oncolytic virus data at SITC 2021
05 Oct 2021 //
PHARMAFILE
BioInvent International AB: Interim report January-June 2021
26 Aug 2021 //
PRNEWSWIRE
Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001,
27 May 2021 //
BUSINESSWIRE
BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 BI-1808
06 Apr 2021 //
PRNEWSWIRE
BioInvent presents proof-of-concept data on anti-FcyRIIB antibody BI-1607
11 Mar 2021 //
PRNEWSWIRE
BioInvent presents proof-of-concept data on anti-FcyRIIB BI-1607 at AACR
10 Mar 2021 //
PRNEWSWIRE
Transgene and BioInvent enrol first subject in solid tumour trial
02 Mar 2021 //
CLINICALTRIALSARENA
Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial
01 Mar 2021 //
BUSINESSWIRE
Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial
25 Feb 2021 //
BUSINESSWIRE
BioInvent Phase I/IIa data suggest BI-1206 restores activity of rituximab
28 Jan 2021 //
PRNEWSWIRE
BioInvent has enrolled first in a Ph I/IIa trial of the first-in-class BI-1808
26 Jan 2021 //
PRNEWSWIRE
BioInvent to host Key Opinion Leader call on BI-1206 for relapsed or refractory
20 Jan 2021 //
PRNEWSWIRE
Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa
19 Jan 2021 //
BIOSPACE
Transgene and BioInvent Receive Approval From ANSM Ph I/IIa Trial BT-001
18 Jan 2021 //
BUSINESSWIRE
BioInvent streamlines agreement on anti-Fc?RllB antibody, BI-1206
11 Jan 2021 //
PRNEWSWIRE
BioInvent restructures clinical development pact with Cancer Research UK
11 Jan 2021 //
PHARMABIZ
BioInvent and Transgene receive CTA approval for Ph l/lla trial BT-001
22 Dec 2020 //
PRNEWSWIRE
Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic
21 Dec 2020 //
BUSINESSWIRE
Transgene & BioInvent Receive CTA Approval for Ph1/2a Trial of Oncolytic BT-001
21 Dec 2020 //
BUSINESSWIRE
Resolutions at the Extraordinary General Meeting in BioInvent on November 27
27 Nov 2020 //
PRNEWSWIRE
BioInvent and Cantargia sign MFG agreement for monoclonal antibody CAN10
25 Nov 2020 //
MEDICIRCLE
BioInvent and Transgene present data on next generation oncolytic virus BT-001
09 Nov 2020 //
PRNEWSWIRE
BioInvent presents promising new clinical & preclinical data BI-1206
04 Nov 2020 //
PRNEWSWIRE
BioInvent receives Denmark regulatory approval to begin phI/IIa of BI-1808
27 Oct 2020 //
PHARMABIZ
BioInvent licenses anti-Fc?RllB antibody BI-1206 to CASI Pharmaceuticals
26 Oct 2020 //
PRNEWSWIRE
CTA approval of BioInvent`s BI-1808, a first-in-class anti-TNFR2 ,Ph I/Iia
26 Oct 2020 //
PRNEWSWIRE
BioInvent receives €2 million milestone from Daiichi Sankyo
21 Oct 2020 //
BIOSPACE
BioInvent to present data on BI-1808, an anti-TNFR2 antibody
15 Oct 2020 //
PRNEWSWIRE
BioInvent to present data on BI-1808, an anti-TNFR2 antibody, at the SITC
14 Oct 2020 //
PRNEWSWIRE
Transgene and BioInvent to Present Data on Oncolytic Virus BT-001
14 Oct 2020 //
BIOSPACE
BioInvent`s BI-1206 could improve treatment in several cancers
21 Jul 2020 //
PRNEWSWIRE
BioInvent Extends Research Collaboration and License Agreement With Pfizer Inc.
01 Jul 2020 //
PRNEWSWIRE
BioInvent a CTA for a Ph I/IIa trial of BI-1808, A First-in-class Anti-TNFR2
30 Jun 2020 //
PRNEWSWIRE
BioInvent begins phase I/IIa trial of BI-1206 in combo
26 Jun 2020 //
PHARMABIZ
BioInvent Enrolls First Patient in Ph I/IIa Trial of BI-1206 in Combo KEYTRUDA
22 Jun 2020 //
PRNEWSWIRE
Transgene’s and BioInvent’s BT-001 Achieves Outstanding Tumor Cure Rates
22 Jun 2020 //
BUSINESSWIRE
BioInvent and Transgene`s BT-001 Achieves Outstanding Tumor Cure Rates
22 Jun 2020 //
PRNEWSWIRE
BioInvent presents promising new data from anti-TNFR2 programme at AARC meeting
18 May 2020 //
PHARMABIZ
BioInvent Expands Anti-TNFR2 Program by Selecting Second Monoclonal Antibody
15 May 2020 //
PRNEWSWIRE
Transgene and BioInvent Present Preclinical Data Demonstrating BT-001’s
15 May 2020 //
BUSINESSWIRE
BioInvent signs manufacturing agreement with US cell therapy company
04 May 2020 //
PHARMABIZ
BioInvent Reports Promising Progress in Pha I/lla Trial of Lead Program BI-1206
14 Apr 2020 //
PR NEWSWIRE
BioInvent & SkylineDx to Collaborate on Patient Stratification Impact BI-1206
25 Mar 2020 //
PR NEWSWIRE
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding
03 Mar 2020 //
BIOSPACE
BioInvent extends research collaboration with Pfizer
24 Dec 2019 //
BIOSPECTRUM ASIA
BioInvent, Cancer Research UK Sign Manufacturing Pact
24 Oct 2019 //
CONTRACT PHARMA
